Results 31 to 40 of about 821 (130)
Sex‐specific associations between Glutaminyl Cyclase and Alzheimer's Disease biomarkers [PDF]
Alzheimers DementAbstract Background Glutaminyl‐peptide cyclotransferase (QPCT) catalyzes the formation of pyroglutamate‐modified amyloid‐beta (pGlu‐Aβ). pGlu‐Aβ is a neurotoxic and aggregation‐prone form of Aβ that accelerates plaque formation and contributes to Alzheimer's Disease (AD).
de Bittencourt M +6 more
europepmc +2 more sources
Structure of glutaminyl cyclase fromDrosophila melanogasterin space groupI4 [PDF]
Acta Crystallographica Section F: Structural Biology Communications, 2013 Petr Kolenko +2 more
exaly +2 more sources
Role of glutaminyl cyclases in thyroid carcinomas [PDF]
Endocrine-Related Cancer, 2012 CCL2 is a chemokine known to recruit monocytes/macrophages to sites of inflammation. CCL2 is also associated with tumor progression in several cancer types. Recently, we showed that the N-terminus of CCL2 is modified to a pyroglutamate (pE)-residue by both glutaminyl cyclases (QC (QPCT)) and its isoenzyme (isoQC (QPCTL)).
Astrid, Kehlen +7 more
openaire +2 more sources
Evidence for tissue‐specific forms of glutaminyl cyclase [PDF]
FEBS Letters, 1999 Glutaminyl cyclase (QC) is responsible for the presence of pyroglutamyl residues in many neuroendocrine peptides. An examination of the bovine tissue distribution of QC immunoreactivity, enzyme activity, and mRNA confirmed that QC was abundant in brain and pituitary by all three measures.
Sykes, Paul A. +3 more
openaire +2 more sources
Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. [PDF]
Proceedings of the National Academy of Sciences, 1987 Extracts from bovine pituitary were found to contain an activity catalyzing the conversion of glutaminyl peptides such as [Gln1]gonadotropin-releasing hormone, [Gln1, Gly4]thyrotropin-releasing hormone (H-Gln-His-Pro-Gly-OH), and H-Gln-Tyr-Ala-OH to the respective pyroglutamyl peptides.
W H, Fischer, J, Spiess
openaire +2 more sources
Journal of Translational Medicine, 2006 Background In recent years encouraging progress has been made in developing vaccine treatments for cancer, particularly with melanoma. However, the overall rate of clinically significant results has remained low.
Gillis John
doaj +1 more source
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends
Drug Discovery Today, 2023 Glutaminyl cyclase (QC) activity has been identified as a key effector in distinct biological processes. Human glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like (QPCTL) are considered attractive therapeutic targets in many human disorders, such as neurodegenerative diseases, and a range of inflammatory conditions ...
Judite R M, Coimbra +3 more
openaire +2 more sources
Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site
BMC Biology, 2004 Background Glutaminyl cyclase (QC) forms the pyroglutamyl residue at the amino terminus of numerous secretory peptides and proteins. We previously proposed the mammalian QC has some features in common with zinc aminopeptidases.
Misquitta Stephanie A +3 more
doaj +1 more source
Biomolecules, 2022 The deposition of β-amyloid peptides and of α-synuclein proteins is a neuropathological hallmark in the brains of Alzheimer’s disease (AD) and Parkinson’s disease (PD) subjects, respectively. However, there is accumulative evidence that both proteins are
Alexandra Bluhm +6 more
doaj +1 more source
Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics [PDF]
The FEBS Journal, 2009 Glutaminyl cyclases (QCs) catalyze the formation of pyroglutamate residues at the N‐terminus of several peptides and proteins from plants and animals. Recently, isoenzymes of mammalian QCs have been identified. In order to gain further insight into the biochemical characteristics of isoQCs, the human and murine enzymes were expressed in the secretory ...
Anett, Stephan +6 more
openaire +2 more sources